Nobelpharma

Nobelpharma Co., Ltd., based in Chūō, Tokyo, was founded in 2003 to bring medicines for rare diseases and unmet medical needs to the Japanese market, often licensing products approved elsewhere and running the Japanese trials needed for approval. It is lead sponsor of several phase 3 cancer trials registered on ClinicalTrials.gov. Its product list includes two cancer medicines: Cosmegen (dactinomycin) for Wilms tumour, choriocarcinoma and paediatric solid tumours, and Zanosar (streptozocin) for gastroenteropancreatic neuroendocrine tumours, alongside Unitalc (talc) for malignant pleural effusion.